PIK3CD and neoplasm: Emerging evidence suggests that inhibition of the PI3K/mTOR pathway enhances the efficacy of immunotherapy through multiple mechanisms, including modulation of the tumor microenvironment, epigenetic reprogramming, and direct effects on immune cell function [72].